BD Rowa ’s Post

GeneTraQ provides deep search, sort, and filter functions to drill down to the data you need to understand key technological, regulatory, clinical, and commercial trends. Schedule a demo of this unique database at www.theratraq.com/genetraq #GeneTherapy #RareDisease #StrategySupport #CriticalInsights #StrategicDecisionMaking

In #REMEDi4ALL, we have a unique combination of expertise to address the complexities of #DrugRepurposing. In this quote, Prof. Zoltán Kaló, CEO of Syreon Research Institute (a #R4ALL partner) shares his thoughts about how we need to reconsider the entire drug repurposing business model. ➡️ More about #R4ALL here: https://lnkd.in/d3V2qYdS

"Time is of the essence in the biopharma space, and it is being lost to poor data management." It seems many biopharma organizations are grappling with a similar problem: unorganized data that leads to delays, costing the company money and IP exclusivity. Read more about how IDBS helps to solve this problem below: https://lnkd.in/emaEv7Ez

Are you heading to the Intellus Worldwide conference next month?! Our team is headed there and would love to catch up! Let us know if you're going! ⤵ #Pharma #Analytics #Consulting #Healthcare #ConsumerInsights #IntellusWW #WeAreIntellusWW #IntellusWorldWide #RecknerHealthcare

This morning Pharming Group N.V. published its fourth quarter and full year 2023 financial results. To read the press release please click here: https://bit.ly/3Tit8TK As a reminder, management will hold an analyst and investor call today March 14 at 13:30 CET/08:30 EDT to discuss the fourth quarter and full year 2023. Information for the call can be found in the press release. #4Q23 #FY23 #financialresults #pharminggroup

This morning Pharming Group N.V. reported its first quarter 2024 financial results and provided a business update. To read the press release please click here: https://bit.ly/44ywJT9 As a reminder, management will hold an analyst and investor call today May 8 at 13:30 CEST/07:30 EDT to discuss the first quarter 2024. Information for the call can be found in the press release. #1Q23 #financialresults #pharminggroup

Great first quarter for Pharming Group N.V. with a substantial increase in sales,mainly thanks to Joenja. Pharming posted a sharp increase in sales in the first quarter of this year, thanks to the commercial launch of Joenja in the United States and higher sales of Ruconest. This was revealed Wednesday morning by figures from the biotech company. Sales increased 31 percent year-on-year last quarter to $55.6 million. Sales from Ruconest rose 8 percent year-on-year to $46.0 million. Sales with Joenja were $9.6 million, good for a 21 percent increase from the fourth quarter of 2023. Pharming thus says it is on track to achieve projected sales of $280 million to $295 million for 2024. That would increase sales 14 to 20 percent year over year. At the end of March, Pharming had 203.5 million euros in cash. A refinancing was completed at the end of the quarter by issuing 100 million euros in convertible bonds maturing in 2029. CEO Sijmen de Vries spoke of a strong first quarter. "We now have 83 patients undergoing reimbursed Joenja therapy in the U.S. and more patients are enrolled and pending. Another 138 patients worldwide are receiving treatment with leniolisib through one of our access programs or ongoing clinical trials," the top executive said. Pharming is looking at opportunities to launch Joenja in other countries as well. Just last week, Joenja was approved by regulators in Israel. From Canadian and Australian regulators, Pharming hopes to get good news this year and next year as well. Speaking to ABM Financial News, De Vries said he also sees many opportunities in leniolisib for additional indications beyond the rare immune disease APDS. De Vries spoke of a "pipeline in a product, a hidden gem." Pharming plans to conduct an initial Phase II study of leniolisib's chances for additional indications. "We have a product that has already been found to be safe and has the potential to reach a much larger target market," the top executive stated. Below the line, a loss of $12.4 million remained last quarter, roughly equal to the loss a year earlier.

Pharmacogenomics (PGx) can lead to better overall quality of care by making sure that medications are prescribed with the specific individual in mind, rather than guessing what may work best under the “standard of care” paradigm. Access our latest white paper here. #moleculardiagnostics https://lnkd.in/eqQpfrcz

#Pharma Community: 𝐈𝐬 𝐭𝐡𝐞 𝐪𝐮𝐚𝐧𝐭𝐢𝐭𝐲 𝐨𝐟 𝐬𝐚𝐦𝐩𝐥𝐞𝐬 𝐲𝐨𝐮𝐫 𝐠𝐫𝐞𝐚𝐭𝐞𝐬𝐭 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞❓ If that's the case, you will 𝗟𝗢𝗩𝗘 the new Echo® MS+ system! Get high-quality data, analytical flexibility and high sample throughput, so you can make the right decisions, today. Watch this video to learn how this is possible. More info here 👉 https://bit.ly/3SHeJ4I #PharmaDiscovery #AcousticDropletEjection #ADE #OpenPortInterface #OPI #AcousticEjectionMassSpectrometry #AEMS #MassSpectrometry #HighThroughputScreening #HighThroughputWorkflows #EchoMSPlus #IntegratedSolutions #SLAS2024 #ProductLaunch #Innovation

Dive into the essentials of MoCRA with our latest Quick Facts video! Understand key Regulatory insights in just a minute. https://lnkd.in/dMwBbe4S #MoCRA #QuickFacts #Cosmetics #USCosmetics #FreyrSolutions